UPDATE : Monday, August 3, 2020
상단여백
HOME Pharma
Daewoong promotes botulinum toxin Nabota in Dubai
  • By So Jae-hyeon
  • Published 2018.03.21 15:47
  • Updated 2018.03.21 15:47
  • comments 0

Daewoong Pharmaceutical has begun pushing international marketing activities to expand its share in the overseas market.

The drugmaker introduced self-developed botulinum toxin Nabota at the Dubai Derma 2018, held from Monday to Wednesday at the Dubai International Convention and Exhibition Center in the United Arab Emirates.

The event was the 18th edition of the largest dermatology and laser conference and exhibition in the Middle East and North Africa. This year, more than 15,000 participants from 100 countries attended the meeting.

Daewoong has attended the event every year since 2013 to promote Nabota’s brand to the global market.

The Korean company held a joint promotion session with its UAE-based partner firm Dansys, which had signed a deal with Daewoong to sell Nabota in the Middle East region. Specialist physicians and corporate executives visited Nabota exhibition booth, enquiring about the product, according to Daewoong.

Participants actively asked questions about Nabota at a presentation session by Turkish plastic surgeon Ismail Kucuker and Korean plastic surgeon Choi Hang-seok, who explained about benefits of Nabota and treatment methods utilizing latest procedures with Nabota.

“I was able to confirm the quick effect of Nabota after using it myself for a procedure, and the patient was highly satisfied because of the long duration. This seems to be due to the high-purity refining method in manufacturing Nabota and the advanced decompression drying process,” Choi said.

After the local release in 2014, Nabota was launched in Thailand, the Philippines, South America, Mexico, and Vietnam. Daewoong also signed deals to export the product to Saudi Arabia, UAE, Egypt, Brazil, and India.

In January, Daewoong obtained the China Food and Drug Administration’s nod for the Clinical Trial Application (CTA) to conduct a phase-3 study on Nabota. Within this year, the company aims to get approvals from the U.S. Food and Drug Administration and European Medicines Agency and release the product in the U.S. and Europe.

sjh@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by So Jae-hyeon
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top